FTC Pulls OptumRx Insulin Price Case To Review Final Deal
The Federal Trade Commission's third and final settlement resolving an in-house case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes is in sight after the agency on Friday...To view the full article, register now.
Already a subscriber? Click here to view full article